DNA methylation changes in heart failure reactivate fetal natriuretic peptide genes (ANP, BNP), providing both biomarker insights and targets for epigenetic-based precision medicine.
Fetal gene reactivation via epigeneticsH3K9 hypomethylation at ANP and BNP promoters drives their upregulation in failing hearts
What the researchers found
Hypomethylation at the H3K9 promoter of ANP and BNP genes reactivates fetal gene expression in failing hearts, while broader epigenetic changes drive metabolic and structural maladaptation.
Why it matters
Understanding why BNP and ANP rise in heart failure at the epigenetic level could enable precision medicine — matching patients to therapies based on their molecular profile rather than one-size-fits-all treatment.
The numbers in context
ANP/BNP H3K9 promoter hypomethylation; KLF15 hypermethylation; miR-10a/155/31/92 prognostic; therapeutics: hydralazine, statins, apabetalone, omega-3
How the study worked
Narrative review mapping epigenetic mechanisms (DNA methylation, histone modifications, miRNAs) in heart failure pathogenesis, with proposed clinical research strategy (EPIKO-STORM).
Who was studied
Review of epigenetic studies in heart failure patients including heart transplant recipients
What this study cannot tell us
Review with proposed framework (EPIKO-STORM) that has not been clinically validated; epigenetic therapies for heart failure remain largely in trials; causal relationships not fully established.
How to read the evidence
Comprehensive review synthesizing epigenetic, genetic, and clinical data, but proposed EPIKO-STORM framework is theoretical and clinical applications remain investigational.
When this study was published
Published in 2020; epigenetic approaches to cardiovascular disease have continued to advance with new clinical trial data.
The bigger picture
This review positions natriuretic peptides not just as passive heart failure markers but as epigenetically regulated molecules whose reactivation is part of the disease mechanism — opening therapeutic possibilities.
Questions still open
- Can epigenetic therapies prevent the reactivation of fetal natriuretic peptide genes in early heart failure?
- Will epigenetic stratification of heart failure patients improve treatment outcomes?
- Do BNP levels correlate with specific methylation patterns that predict treatment response?
Common questions
Why do BNP levels rise in heart failure?
What is precision medicine for heart failure?
Read the original research
Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics.
American heart journal, 224, 113-128
Citation
Napoli, Claudio; Benincasa, Giuditta; Donatelli, Francesco; Ambrosio, Giuseppe. (2020). Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics.. American heart journal, 224, 113-128. https://doi.org/10.1016/j.ahj.2020.03.007